Skip to content

Efficacy of unani formulation in the treatment of Lichen Planus

Clinical study of Lichen Planus and therapeutic evaluation of Unani formulation in its management - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057463
Enrollment
30
Registered
2023-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L438- Other lichen planus

Interventions

Intervention1: Majoon Musaffiye Aazam Marham e hina: Majoon Musaffiye Aazam (6gm) orally twice daily for 45 days and Marham e hina locally twice daily for 45 days Control Intervention1: Deflazacort 6

Sponsors

Department of Amraz e Jild wa Zohrawiya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of Lichen Planus Clinically stable patients Patients of either sex Patients having age group of 18 to 60 years Patients who are willing to be a part of our study

Exclusion criteria

Exclusion criteria: Patient below and above the age of 18 years and 60 years Patients who are not willing to be a part of study Patient suffering from any other type of skin diseases like psoriasis Eczema Seborrheic Dermatitis dermatophytosis and Lupus Erythematosus Patient suffering from systemic and metabolic diseases like DM and prediabetes severe asthma Cardiac diseases Chronic Renal failure History of taking Conventional and Alternative Medicine therapy of present disease within the previous 7 days Pregnant & Lactating Women

Design outcomes

Primary

MeasureTime frame
Improvement in Lichen Planus Severity Index Improvement in Dermatology Life Quality Index. Improvement in Photograph of affected area.Timepoint: Assessment of all parameters at inititation of the study at 0 day 15 day 30 day & 45 day of the study.

Secondary

MeasureTime frame
Itching Scaling Violaceous, Hyperpigmented PapulesTimepoint: Assessment of all the symptoms at initiation of the study at 0 day 15 day 30 day & 45 day of the study.

Countries

India

Contacts

Public ContactMalik Nuzhat Fatima

Ajmal khan tibbya college AMU

aqdas2005@gmail.com9412329198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026